Literature DB >> 7908518

Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D.

K Asakuno1, K Kohno, T Uchiumi, T Kubo, S Sato, M Isono, M Kuwano.   

Abstract

The human multidrug resistance 1 (MDR1) gene is an SOS gene that responds to environmental stress including various anticancer agents. The chloramphenicol acetyltransferase (CAT) gene was linked to various lengths of MDR1 promoter, and these constructs were integrated into the genome of human cancer KB cells. Using these cell lines, we previously demonstrated that various environmental stimuli lead to an increased abundance of both CAT enzymatic activity and CAT mRNA in a sequence dependent manner. We examined the molecular mechanism of this stress response using actinomycin D, a potent RNA synthesis inhibitor. We found that CAT activity was significantly increased more than 10 fold by actinomycin D itself without comparable elevation of CAT mRNA. CAT induction was, however, lost in the presence of a deletion from position -136 to -76. Gel mobility shift assays showed that the specific DNA binding activity of the transacting protein, MDR-NF1/YB-1, which binds to the inverted CCAAT box, was augmented in nuclear extracts from the cells treated with actinomycin D. We also found that actinomycin D increased the steady state levels of MDR-NF1/YB-1 mRNA, which encodes the inverted CCAAT box binding protein. These results indicate that MDR-NF1/YB-1 mediates the response of the MDR1 gene to environmental stress.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908518     DOI: 10.1006/bbrc.1994.1390

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Reciprocal interaction between two cellular proteins, Puralpha and YB-1, modulates transcriptional activity of JCVCY in glial cells.

Authors:  M Safak; G L Gallia; K Khalili
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter.

Authors:  Y Makino; T Ohga; S Toh; K Koike; K Okumura; M Wada; M Kuwano; K Kohno
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

3.  Physical and functional interaction between the Y-box binding protein YB-1 and human polyomavirus JC virus large T antigen.

Authors:  M Safak; G L Gallia; S A Ansari; K Khalili
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 4.  Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?

Authors:  D Dolfini; R Mantovani
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

5.  Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

Authors:  T Abe; T Mori; Y Wakabayashi; M Nakagawa; S P Cole; K Koike; M Kuwano; S Hori
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

6.  Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent.

Authors:  U Stein; W Walther; R H Shoemaker
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

7.  Transcriptional regulation of MDR genes.

Authors:  K W Scotto; D A Egan
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.

Authors:  Y Fujiwara-Okada; Y Matsumoto; J Fukushi; N Setsu; S Matsuura; S Kamura; T Fujiwara; K Iida; M Hatano; A Nabeshima; H Yamada; M Ono; Y Oda; Y Iwamoto
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

Review 9.  Cold shock proteins: from cellular mechanisms to pathophysiology and disease.

Authors:  Jonathan A Lindquist; Peter R Mertens
Journal:  Cell Commun Signal       Date:  2018-09-26       Impact factor: 5.712

10.  YB-3 substitutes YB-1 in global mRNA binding.

Authors:  D N Lyabin; I A Eliseeva; E A Smolin; A N Doronin; K S Budkina; I V Kulakovskiy; L P Ovchinnikov
Journal:  RNA Biol       Date:  2020-01-16       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.